A review of recent advances in the treatment of adults with complicated urinary tract infection

References

• Nicolle LE. Epidemiology of urinary tract infections. Clin Microbiol Newsl. 2002;24(18): 135–140.
   Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113 Suppl 1A(1):5S–13S.
   Google Scholar
• Foxman B, Barlow R, D’Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509–515.
   Google Scholar
• Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
   Google Scholar
• Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311(8):844–854.
   Google Scholar
• Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin North Am. 2014;28(1):75–89.
   Google Scholar
• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–e120.
   Google Scholar
• EAU Guidelines. Edn. EAU Guidelines on Urological Infections. Presented at the EAU Annual Congress Amsterdam, The Netherlands 2022.
   Google Scholar
• Pera A, Campos C, López N, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50–55.
   Google Scholar
• McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. 2009;21(4):418–424.
   Google Scholar
• Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15–21.
   Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–1310.
   Google Scholar
• Sinapidis D, Kosmas V, Vittoros V, et al. Progression into sepsis: an individualized process varying by the interaction of comorbidities with the underlying infection. BMC Infect Dis. 2018;18(1):242.
   Google Scholar
• Esper AM, Moss M, Lewis CA, et al. The role of infection and comorbidity: factors that influence disparities in sepsis. Crit Care Med. 2006;34(10):2576–2582.
   Google Scholar
• Bajaj JS, Kamath PS, Reddy KR. The evolving challenge of infections in cirrhosis. N Engl J Med. 2021;384(24):2317–2330.
   Google Scholar
• O’Neil J. Tackling drug-resistant infections globally: final report and recommendations. In: Ro A, editor. Resistance. London (UK): Government of the United Kingdom; 2016. Vol. 1 .p. 84.
   Google Scholar
• Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325): 629–655.
   Google Scholar
• Dyar OJ, Huttner B, Schouten J, et al., ESGAP (ESCMID Study Group for Antimicrobial stewardship). What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793–798.
   Google Scholar
• Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73–79.
   Google Scholar
• Sanchez GV, Babiker A, Master RN, et al. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680–2683.
   Google Scholar
• Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45(3):273–280.
   Google Scholar
• Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging. 2001;18(4):243–254.
   Google Scholar
• Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653–660.
   Google Scholar
• The review on antimicrobial resistance, chaired by Jim O’Neill. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Dec 2014. http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-Review-Paper-Tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.
   Google Scholar
• Chen YH, Ko WC, Hsueh PR. Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Expert Opin Pharmacother. 2013;14(5):587–596.
   Google Scholar
• Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14(4):933–951.
   Google Scholar
• Gupta K, Bhadelia N. Management of urinary tract infections from multidrug-resistant organisms. Infect Dis Clin North Am. 2014;28(1):49–59.
   Google Scholar
• Khawcharoenporn T, Vasoo S, Singh K. Urinary tract infections due to multidrug-resistant Enterobacteriaceae: prevalence and risk factors in a Chicago emergency department. Emerg Med Int. 2013;2013:258517.
   Google Scholar
• Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38(7–8):1148–1152.
   Google Scholar
• Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis. 2016;63(7):960–965.
   Google Scholar
• Smithson A, Chico C, Ramos J, et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis. 2012;31(4):423–430.
   Google Scholar
• Linsenmeyer K, Strymish J, Gupta K. Two simple rules for improving the accuracy of empiric treatment of multidrug-resistant urinary tract infections. Antimicrob Agents Chemother. 2015;59(12):7593–7596.
   Google Scholar
• Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11(3):297–308.
   Google Scholar
• Eliakim-Raz N, Babitch T, Shaw E, et al. Risk factors for treatment failure and mortality among hospitalized patients with complicated urinary tract infection: a multicenter retrospective cohort study (RESCUING Study Group). Clin Infect Dis. 2019;68(1):29–36.
   Google Scholar
• Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196(7):856–863.
   Google Scholar
• Spellberg B. The new antibiotic mantra-”Shorter is better”. JAMA Intern Med. 2016;176(9):1254–1255.
   Google Scholar
• Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. Ann Intern Med. 2019;171(3):210–211.
   Google Scholar
• Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: a systematic review of randomized controlled trials. Pharmacotherapy. 2018;38(6):674–687.
   Google Scholar
• Erba L, Furlan L, Monti A, et al. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. Intern Emerg Med. 2021;16(2):313–323.
   Google Scholar
• Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection– 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013;68(10):2183–2191.
   Google Scholar
• Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008;71(1):17–22.
   Google Scholar
• Johnson JR, Lyons MFs2nd, Pearce W, et al. Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis. 1991;163(2):325–330.
   Google Scholar
• Jang YR, Eom JS, Chung W, et al. Prolonged fever is not a reason to change antibiotics among patients with uncomplicated community-acquired acute pyelonephritis. Medicine (Baltimore). 2019;98(43):e17720.
   Google Scholar
• Johnson JR, Russo TA. Acute pyelonephritis in adults [published correction appears in. N Engl J Med. 2018;378(11):1069. N Engl J Med. 2018;378(1):48-59.
   Google Scholar
• Monmaturapoj T, Montakantikul P, Mootsikapun P, et al. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis. Int J Infect Dis. 2012;16(12):e843–e849.
   Google Scholar
• Norrby SR. Levofloxacin. Expert Opin Pharmacother. 1999;1(1):109–119.
   Google Scholar
• Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014;42(10):1033–1038.
   Google Scholar
• Meier S, Weber R, Zbinden R, et al. Extended-spectrum β-lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39(4):333–340.
   Google Scholar
• Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012;74(1):62–67.
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) [published online ahead of print, 2022 Apr 19]. Clin Infect Dis. 2022;75:ciac268.
   Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–547.
   Google Scholar
• Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial [published correction appears in JAMA. JAMA. 2019;321(23):2370. JAMA. 2018;320(10):984-994.
   Google Scholar
• Denisuik AJ, Lagacé-Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother. 2013;68(Suppl 1):i57–i65.
   Google Scholar
• Bouchillon SK, Badal RE, Hoban DJ, et al. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013;35(6):872–877.
   Google Scholar
• Karlowsky JA, Lagacé-Wiens PR, Simner PJ, et al. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother. 2011;55(7):3169–3175.
   Google Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the infectious diseases society of America. Clin Infect Dis. 2010;50(5):625–663.
   Google Scholar
• Harris PN, Yin M, Jureen R, et al. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2015;4(1):14.
   Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60(9):1319–1325.
   Google Scholar
• Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, et al. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159–4169.
   Google Scholar
• Tullos JB, Stoudenmire LL, Pouliot JD. Piperacillin-tazobactam versus carbapenems for the treatment of nonbacteremic urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Hosp Pharm. 2020;55(1):44–49.
   Google Scholar
• McLaughlin M, Advincula MR, Malczynski M, et al. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131–5133.
   Google Scholar
• Patel N, Harrington S, Dihmess A, et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J Antimicrob Chemother. 2011;66(7):1600–1608.
   Google Scholar
• Yoon YK, Kim JH, Sohn JW, et al. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2017;49(4):410–415.
   Google Scholar
• Sharara SL, Amoah J, Pana ZD, et al. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing organisms? Clin Infect Dis. 2020;71(8):e331–e337.
   Google Scholar
• Dizbay M, Özger HS, Ö K, et al. Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam. Turk J Med Sci. 2016;46(6):1760–1764.
   Google Scholar
• Anderson DT, Albrecht B, Jones KA, et al. Efficacy of noncarbapenem β-lactams compared to carbapenems for extended-spectrum β-lactamase-producing enterobacterales urinary tract infections. Open Forum Infect Dis. 2022;9(3):ofac034.
   Google Scholar
• Henderson A, Paterson DL, Chatfield MD, et al. Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. Clin Infect Dis. 2021;73(11):e3842–e3850.
   Google Scholar
• Harada Y, Morinaga Y, Kaku N, et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2014;20(11):O831–O839.
   Google Scholar
• Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380(9840):484–490.
   Google Scholar
• Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583–1590.
   Google Scholar
• Bientinesi R, Murri R, Sacco E. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opin Pharmacother. 2020;21(6):637–644.
   Google Scholar
• Ren H, Li X, Ni ZH, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Int Urol Nephrol. 2017;49(3):499–507.
   Google Scholar
• Elbaz M, Zadka H, Weiss-Meilik A, et al. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. J Antimicrob Chemother. 2020;75(8):2307–2313.
   Google Scholar
• Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2/3 randomized trial. Clin Infect Dis. 2019;69(12):2045–2056.
   Google Scholar
• Rosso-Fernández C, Sojo-Dorado J, Barriga A, et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open. 2015;5(3):e007363.
   Google Scholar
• Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents. 2012;39(3):271–272.
   Google Scholar
• Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44(3):182–189.
   Google Scholar
• Zhu Y, Xiao T, Wang Y, et al. Socioeconomic burden of bloodstream infections caused by carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2021;14:5385–5393. DOI:10.2147/IDR.S341664.
   Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–1798.
   Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36.
   Google Scholar
• Potter RF, D’Souza AW, Dantas G. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat. 2016;29:30–46.
   Google Scholar
• Wood MJ, Farrell W. Comparison of urinary excretion of tobramycin and gentamicin in adults. J Infect Dis. 1976;134(Supp l):S133–S136.
   Google Scholar
• Castanheira M, Davis AP, Mendes RE, et al. In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother. 2018;62(8):e00313–18.
   Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–740.
   Google Scholar
• Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754–762.
   Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673.
   Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788–799.
   Google Scholar
• Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18(12):1319–1328.
   Google Scholar
• Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017;72(9):2616–2626.
   Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–17.
   Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2):e01964–16.
   Google Scholar
• Castón JJ, Cano A, Pérez-Camacho I, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother. 2022;77(5):1452–1460.
   Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364.
   Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171.
   Google Scholar
• Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921–1931.
   Google Scholar
• De la Calle C, Rodríguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019;53(4):520–524.
   Google Scholar
• Volpicelli L, Venditti M, Ceccarelli G, et al. Place in therapy of the newly available armamentarium for multi-drug-resistant gram-negative pathogens: proposal of a prescription algorithm. Antibiotics (Basel). 2021;10(12):1475.
   Google Scholar
• Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/Avibactam, Meropenem/Vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis. 2019;68(3):519–524.
   Google Scholar
• Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-Expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59(10):6605–6607.
   Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-Avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618.
   Google Scholar
• Papp-Wallace KM, Mack AR, Taracila MA, et al. Resistance to novel β-lactam-β-lactamase inhibitor combinations: the “Price of progress.” Infect Dis Clin North Am. 2020;34(4):773–819.
   Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455.
   Google Scholar
• Tumbarello M, Raffaelli F, Cascio A, et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist. 2022;4(1):dlac022.
   Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–17.
   Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015;59(4):2299–2304.
   Google Scholar
• Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018;37(8):1411–1419.
   Google Scholar
• Wu G, Cheon E. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis. Expert Opin Pharmacother. 2018;19(13):1495–1502.
   Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159–177.
   Google Scholar
• Ramsey C, MacGowan AP. A review of the pharmacokinetics and pharmacodynamics of aztreonam. J Antimicrob Chemother. 2016;71(10):2704–2712.
   Google Scholar
• Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243–16.
   Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878.
   Google Scholar
• Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73(4):1104–1106.
   Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544.
   Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S538–S543.
   Google Scholar
• Longshaw C, Manissero D, Tsuji M, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist. 2020;2(3):dlaa060.
   Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68(10):2286–2290.
   Google Scholar
• Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol. 2020;41(1):1–18.
   Google Scholar
• Bouza E, San Juan R, Muñoz P, et al., Co-operative Group of the European Study Group on Nosocomial Infections, A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). Clin Microbiol Infect. 2001;7(10):523–531.
   Google Scholar
• Lamas Ferreiro JL, Otero J Á, González González L, et al. Pseudomonas aeruginosa urinary tract infections in hospitalized patients: mortality and prognostic factors. PLoS One. 2017;12(5):e0178178.
   Google Scholar
• Meletis G, Bagkeri M. Pseudomonas aeruginosa: multi-drug-resistance development and treatment options. Infection Control. 2013;2:34–45. 10.5772/55616.
   Google Scholar
• Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–192.
   Google Scholar
• Joo EJ, Kang CI, Ha YE, et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection. 2011;39(4):309–318.
   Google Scholar
• Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37(6):745–751.
   Google Scholar
• Cheong HS, Kang CI, Wi YM, et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis. 2008;27(12):1219–1225.
   Google Scholar
• TP LsJr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007;51(10):3510–3515.
   Google Scholar
• Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49(4):1306–1311.
   Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005;49(2):760–766.
   Google Scholar
• Murri R, Sacco E. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections? Expert Opin Pharmacother. 2021;22(11):1377–1379.
   Google Scholar
• Canton R, Doi Y, Simner PJ. Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol [published online ahead of print, 2022 May 10]. Expert Rev Anti Infect Ther. 2022;1–18. DOI:10.1080/14787210.2022.2071701
   Google Scholar
• Reik R, Tenover FC, Klein E, et al. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis. 2008;62(1):81–85.
   Google Scholar
• Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy. 2010;30(11):1136–1149.
   Google Scholar
• Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother. 2003;52(3):382–388.
   Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–170.
   Google Scholar
• Werner G, Coque TM, Hammerum AM, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008;13(47):19046.
   Google Scholar
• Cole M, Ridley B. Absence of bioactive metabolites of ampicillin and amoxycillin in man. J Antimicrob Chemother. 1978;4(6):580–582.
   Google Scholar
• Cole KA, Kenney RM, Perri MB, et al. Outcomes of Aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections. Antimicrob Agents Chemother. 2015;59(12):7362–7366.
   Google Scholar
• Shah KJ, Cherabuddi K, Shultz J, et al. Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience. Int J Antimicrob Agents. 2018;51(1):57–61.
   Google Scholar
• Williamson JC, Craft DW, Butts JD, et al. In vitro assessment of urinary isolates of ampicillin-resistant enterococci. Ann Pharmacother. 2002;36(2):246–250.
   Google Scholar
• Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13(9):1159–1169.
   Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44(4):1062–1066.
   Google Scholar
• Turnidge J, Kahlmeter G, Cantón R, et al. European committee on antimicrobial susceptibility testing. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clin Microbiol Infect. 2020;26(8):1039–1043.
   Google Scholar
• Chuang YC, Lin HY, Chen PY, et al. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Clin Microbiol Infect. 2016;22(10):890.e1–890.e7.
   Google Scholar
• Britt NS, Potter EM, Patel N, et al. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of Vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017;64(5):605–613.
   Google Scholar
• Chuang YC, Lin HY, Chen PY, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis. 2017;64(8):1026–1034.
   Google Scholar
• Fisher L, North D. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agents. 2009;33(5):493–494.
   Google Scholar
• Ramaswamy DP, Amodio-Groton M, Scholand SJ. Use of daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections: a short case series. BMC Urol. 2013;13(1):33.
   Google Scholar
• Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy. 2004;24(1):41–57.
   Google Scholar
• Raad II, Hanna HA, Boktour M, et al. Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrob Agents Chemother. 2005;49(12):5046–5050.
   Google Scholar
• Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents. 2001;18(3):253–258.
   Google Scholar
• Wagenlehner FM, Naber KG. New drugs for Gram-positive uropathogens. Int J Antimicrob Agents. 2004;24(Suppl 1):S39–S43.
   Google Scholar
• Wingler MJ, Patel NR, King ST, et al. Linezolid for the treatment of urinary tract infections caused by vancomycin-resistant enterococci. Pharmacy (Basel). 2021;9(4):175.
   Google Scholar
• Pontefract BA, Rovelsky SA, Madaras-Kelly KJ. Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus. SAGE Open Med. 2020;8:2050312120970743. Published 2020 Nov 4. DOI:10.1177/2050312120970743.
   Google Scholar
• Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43(4):518–524.
   Google Scholar
• Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol. 2008;46(5):1892–1893.
   Google Scholar
• Belley A, Arhin FF, Moeck G. Evaluation of oritavancin dosing strategies against vancomycin-Resistant Enterococcus faecium isolates with or without reduced susceptibility to daptomycin in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2017;62(1):e01873–17.
   Google Scholar
• Carvalhaes CG, Sader HS, Streit JM, et al. Activity of oritavancin against gram-positive pathogens causing bloodstream infections in the United States over 10 years: focus on drug-resistant enterococcal subsets (2010-2019). Antimicrob Agents Chemother. 2022;66(2):e0166721.
   Google Scholar
• Centers for Disease Control (CDC). (2019) Antibiotic resistance threats in the United States. Atlanta, GA: U.S.: Department of Health and Human Services, CDC. Available at https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf (Accessed 15 May 2022).
   Google Scholar
• Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138.
   Google Scholar
• Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358(12):1271–1281.
   Google Scholar
• Lenhard JR, Smith NM, Bulman ZP, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61(3):e01268–16.
   Google Scholar
• Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist. 2021;24:136–147.
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America guidance on the treatment of AmpC β-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and stenotrophomonas maltophilia infections. Clin Infect Dis. 2021;ciab1013. DOI:10.1093/cid/ciab1013
   Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2006;42(12):1819. Dosage error in article text]. Clin Infect Dis. 2005;40(9):1333-1341.
   Google Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801–810.
   Google Scholar
• Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28(5):1008–1011.
   Google Scholar
• Grégoire N, Aranzana-Climent V, Magréault S, et al. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet. 2017;56(12):1441–1460.
   Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699–1709.
   Google Scholar
• Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S544–S551.
   Google Scholar
• Saisho Y, Katsube T, White S, et al. Safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. 2018;62(3):e02163–17.
   Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   Google Scholar
• Malik S, Kaminski M, Landman D, et al. Cefiderocol Resistance in Acinetobacter baumannii: roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3. Antimicrob Agents Chemother. 2020;64(11):e01221–20.
   Google Scholar
• Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3(4):dlab174.
   Google Scholar
• Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66(5):e0214221.
   Google Scholar
• Rando E, Segala FV, Vargas J, et al. Cefiderocol for severe carbapenem-resistant A. baumannii pneumonia: towards the comprehension of its place in therapy. Antibiotics (Basel). 2021;11(1):3.
   Google Scholar
• Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72(11):2021–2024.
   Google Scholar
• Oliva A, Ceccarelli G, De Angelis M, et al. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2020;23:292–296.
   Google Scholar
• Arpi M, Renneberg J. The clinical significance of Staphylococcus aureus bacteriuria. J Urol. 1984;132(4):697–700.
   Google Scholar
• Ackermann RJ, Monroe PW. Bacteremic urinary tract infection in older people. J Am Geriatr Soc. 1996;44(8):927–933.
   Google Scholar
• Walker JN, Flores-Mireles AL, Pinkner CL, et al. Catheterization alters bladder ecology to potentiate Staphylococcus aureus infection of the urinary tract. Proc Natl Acad Sci U S A. 2017;114(41):E8721–E8730.
   Google Scholar
• Demuth PJ, Gerding DN, Crossley K. Staphylococcus aureus bacteriuria. Arch Intern Med. 1979;139(1):78–80.
   Google Scholar
• Baraboutis IG, Tsagalou EP, Lepinski JL, et al. Primary Staphylococcus aureus urinary tract infection: the role of undetected hematogenous seeding of the urinary tract. Eur J Clin Microbiol Infect Dis. 2010;29(9):1095–1101.
   Google Scholar
• Kitano H, Shigemoto N, Koba Y, et al. Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection. World J Urol. 2021;39(2):511–516.
   Google Scholar
• Megged O. Staphylococcus aureus urinary tract infections in children are associated with urinary tract abnormalities and vesico-ureteral reflux. Pediatr Nephrol. 2014;29(2):269–272.
   Google Scholar
• RC MsJr. Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984;14(Suppl D):43–52.
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. Clin Infect Dis. 2011;53(3):319. Clin Infect Dis. 2011;52(3):e18-e55.
   Google Scholar
• Corey GR, Jones RN. Ceftaroline applications for therapy in the United States. Clin Infect Dis. 2012;55(Suppl 3):S171–S172.
   Google Scholar
• Poon H, Chang MH, Fung HB. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther. 2012;34(4):743–765.
   Google Scholar
• Werth BJ, Steed ME, Kaatz GW, et al. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the “seesaw effect.” Antimicrob Agents Chemother. 2013;57(6):2664–2668.
   Google Scholar
• Werth BJ, Barber KE, Ireland CE, et al. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2014;58(6):3177–3181.
   Google Scholar
• Arshad S, Hartman P, Zervos MJ. A novel treatment option for MRSA pneumonia: ceftaroline fosamil-yielding new hope in the fight against a persistent infection. Expert Rev Anti Infect Ther. 2014;12(7):727–729.
   Google Scholar
• Casapao AM, Davis SL, Barr VO, et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58(5):2541–2546.
   Google Scholar
• Tattevin P, Boutoille D, Vitrat V, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother. 2014;69(7):2010–2013.
   Google Scholar
• Sobel JD, Fisher JF, Kauffman CA, et al. Candida urinary tract infections–epidemiology. Clin Infect Dis. 2011;52(Suppl 6):S433–S436.
   Google Scholar
• Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) mycoses study group. Clin Infect Dis. 2000;30(1):14–18.
   Google Scholar
• Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am. 2014;28(1):61–74.
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50.
   Google Scholar
• Schelenz S, Ross CN. Limitations of caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection. BMC Infect Dis. 2006;6(1):126.
   Google Scholar
• Sobel JD, Bradshaw SK, Lipka CJ, et al. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis. 2007;44(5):e46–e49.
   Google Scholar
• Cuervo G, Garcia-Vidal C, Puig-Asensio M, et al. Echinocandins compared to fluconazole for candidemia of a urinary tract source: a propensity score. Clin Infect Dis. 2017;65(8):1431–1433]. [published correction appears in Clin Infect Dis. 2017 Aug 15;65(4):707]. Clin Infect Dis. 2017;64(10):1374-1379.
   Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–637.
   Google Scholar
• Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775–785.
   Google Scholar
• Watkins RR, Deresinski S. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae. Expert Rev Anti Infect Ther. 2017;15(10):893–895.
   Google Scholar